Study of HS235 in Obese Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (HFpEF)

Sponsor
35Pharma Inc
Study ID
NCT07123779
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • HS235 — BIOLOGICAL
    Subcutaneous Injection
  • Placebo — OTHER
    Subcutaneous Injection

Study Details

Study of HS235 in Obese Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction Utilizing Ambulatory Pulmonary Artery Pressure Monitoring

Key Dates

First listed
Aug 14, 2025
Start date
Sep 30, 2025
Status verified
Jul 2025
Primary completion
Sep 30, 2027
Completion
Sep 30, 2028

Study Design

Enrollment
40 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Investigational Product
    HS235 Subcutaneous Injection
  • Placebo Comparator: Placebo
    Subcutaneous Injection

Primary Outcome Measure

Incidence and Number of Adverse Events (AEs) [ Time Frame: Up to 24 weeks ]

Central Contacts

Find similar trials

Nationwide
Heart failure trialsCardiology trialsHeart disease trials

Related Studies